Ixazomib-associated skin exfoliation

Ixazomib-associated skin exfoliation

Saved in:

Bibliographic Details
Main Authors:	Yali Zhang, Long Zhao, Yuancheng Guo, bei liu
Format:	Article
Language:	English
Published:	PAGEPress Publications 2022-04-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	multiple myeloma ixazomib cutaneous adverse events
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/4995
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
by: Benjamin J. Lee, et al.
Published: (2025-06-01)

Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma
by: Xavier Armoiry, et al.
Published: (2019-01-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients
by: Marina Mané-Damas, et al.
Published: (2025-05-01)

Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma
by: Peng Lang, et al.
Published: (2025-01-01)

Cutaneous involvement in multiple myeloma. A rare entity
by: L. Rapparini, et al.
Published: (2025-02-01)

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials
by: Muhammed Favas Karimbanathottathil, et al.
Published: (2024-12-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
by: Jinlong Huang, et al.
Published: (2025-04-01)

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum
by: Yusuke Okayama, et al.
Published: (2025-12-01)

Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma
by: Chang Shan, et al.
Published: (2025-07-01)

Successful usage of external beam radiation to myeloma cutaneous lesions in patient with refractory, relapsed multiple myeloma
by: Chira Ranjan Khadanga, et al.
Published: (2019-01-01)

Keratoacanthoma-like eruption associated with pembrolizumab and dupilumab treated by intralesional triamcinolone: A case report
by: Raphaella Lambert, BA, et al.
Published: (2025-07-01)

A case of multiple myeloma presenting with bullous skin lesions as the initial symptom
by: CHEN Lin, et al.
Published: (2025-04-01)

Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis
by: Zhihui Yang, et al.
Published: (2025-03-01)

Ponatinib-induced psoriasis treated with tildrakizumab
by: Kyle Mueller, BA, et al.
Published: (2025-08-01)

Lamotrigine-Related Skin Rash
by: J. Jokubaitė, et al.
Published: (2023-12-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)

Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-10-01)

Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma
by: B. B. Samura
Published: (2016-06-01)

Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
by: B. B. Samura, et al.
Published: (2020-03-01)

Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-08-01)

Multiple myeloma and cardiovascular risk (a literature review)
by: B. B. Samura, et al.
Published: (2020-11-01)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01)

Adverse drug reactions of first-line antitubercular drugs: A retrospective study on characteristics, management, factors, and impacts
by: Ai Ling Oh, et al.
Published: (2024-10-01)

Tape Strip Profiling of Checkpoint Inhibitor–Associated Dermatitis Highlights Pan-T-Cell Activation: A Pilot Study
by: Camille M. Powers, et al.
Published: (2025-07-01)

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
by: Amman Bhasin, et al.
Published: (2025-02-01)

Thrombotic events in patients with multiple myeloma and their impact on overall survival
by: Haimin Chen, et al.
Published: (2025-12-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Unique skin nodules following COVID-19 vaccination: a case report of cutaneous plasmacytosis and review of the literature
by: Xiaoxi Xu, et al.
Published: (2025-03-01)

Enhancing prognosis in multiple myeloma bone disease: insights from a retrospective analysis of surgical interventions
by: Xiangjun Shi, et al.
Published: (2024-12-01)

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge
by: Ying-Jie Su, et al.
Published: (2025-08-01)

Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
by: E. A. Degtiareva, et al.
Published: (2022-11-01)